Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TRIP12

Gene summary for TRIP12

Gene summary.

Gene information	Species	Human
	Gene symbol	TRIP12
	Gene ID	9320
	Gene name	thyroid hormone receptor interactor 12
	Gene Alias	MRD49
	Cytomap	2q36.3
	Gene Type	protein-coding
	GO ID	GO:0000209
	UniProtAcc	Q14669

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9320	TRIP12	GSM5252136_BPH556PrGA1_Fcol	Human	Prostate	BPH	2.74e-03	2.38e-01	-0.23
9320	TRIP12	GSM5252137_BPH556PrGA2_Fcol	Human	Prostate	BPH	9.89e-07	3.35e-01	-0.23
9320	TRIP12	047563_1562-all-cells	Human	Prostate	BPH	1.31e-06	3.18e-01	0.0791
9320	TRIP12	048752_1579-all-cells	Human	Prostate	BPH	7.00e-42	6.79e-01	0.1008
9320	TRIP12	052095_1628-all-cells	Human	Prostate	BPH	7.81e-30	5.98e-01	0.1032
9320	TRIP12	052097_1595-all-cells	Human	Prostate	BPH	4.41e-28	5.98e-01	0.0972
9320	TRIP12	052099_1652-all-cells	Human	Prostate	BPH	7.00e-23	5.19e-01	0.1038
9320	TRIP12	Dong_P1	Human	Prostate	Tumor	9.33e-21	9.95e-02	0.035
9320	TRIP12	Dong_P3	Human	Prostate	Tumor	1.96e-09	1.41e-01	0.0278
9320	TRIP12	Dong_P5	Human	Prostate	Tumor	2.55e-10	-2.36e-03	0.053
9320	TRIP12	GSM5353215_PA_AUG_PB_1B_S2	Human	Prostate	Tumor	1.77e-08	8.94e-01	0.1557
9320	TRIP12	GSM5353216_PA_PB1A_Pool_1_3_S50_L002	Human	Prostate	Tumor	8.02e-07	7.36e-01	0.159
9320	TRIP12	GSM5353217_PA_PB1A_Pool_2_S107_L004	Human	Prostate	Tumor	3.07e-02	7.23e-01	0.156
9320	TRIP12	GSM5353221_PA_PB2A_Pool_1_3_S25_L001	Human	Prostate	Tumor	1.78e-18	7.89e-01	0.1633
9320	TRIP12	GSM5353222_PA_PB2B_Pool_1_3_S52_L002	Human	Prostate	Tumor	1.78e-18	7.42e-01	0.1608
9320	TRIP12	GSM5353223_PA_PB2B_Pool_2_S26_L001	Human	Prostate	Tumor	1.58e-10	6.82e-01	0.1604
9320	TRIP12	GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001	Human	Prostate	Tumor	9.78e-15	7.17e-01	0.1621
9320	TRIP12	GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002	Human	Prostate	Tumor	1.04e-06	6.30e-01	0.1619
9320	TRIP12	GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002	Human	Prostate	Tumor	4.22e-02	5.26e-01	0.159
9320	TRIP12	GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002	Human	Prostate	Tumor	4.27e-09	5.88e-01	0.1602

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:190332010	Cervix	CC	regulation of protein modification by small protein conjugation or removal	66/2311	242/18723	2.31e-10	3.46e-08	66
GO:003139610	Cervix	CC	regulation of protein ubiquitination	59/2311	210/18723	5.90e-10	7.51e-08	59
GO:00002097	Cervix	CC	protein polyubiquitination	58/2311	236/18723	1.57e-07	7.41e-06	58
GO:003139710	Cervix	CC	negative regulation of protein ubiquitination	28/2311	83/18723	3.32e-07	1.35e-05	28
GO:190332110	Cervix	CC	negative regulation of protein modification by small protein conjugation or removal	29/2311	95/18723	2.15e-06	6.55e-05	29
GO:00165705	Cervix	CC	histone modification	84/2311	463/18723	1.70e-04	2.01e-03	84
GO:00459955	Cervix	CC	regulation of embryonic development	19/2311	64/18723	1.78e-04	2.09e-03	19
GO:20010209	Cervix	CC	regulation of response to DNA damage stimulus	46/2311	219/18723	1.92e-04	2.23e-03	46
GO:00310565	Cervix	CC	regulation of histone modification	33/2311	152/18723	7.97e-04	7.00e-03	33
GO:00510528	Cervix	CC	regulation of DNA metabolic process	65/2311	359/18723	9.25e-04	7.84e-03	65
GO:00705343	Cervix	CC	protein K63-linked ubiquitination	14/2311	56/18723	6.93e-03	3.74e-02	14
GO:1903320	Colorectum	AD	regulation of protein modification by small protein conjugation or removal	86/3918	242/18723	9.43e-08	4.65e-06	86
GO:0051052	Colorectum	AD	regulation of DNA metabolic process	116/3918	359/18723	2.47e-07	1.00e-05	116
GO:0031396	Colorectum	AD	regulation of protein ubiquitination	72/3918	210/18723	4.50e-06	1.21e-04	72
GO:0000209	Colorectum	AD	protein polyubiquitination	78/3918	236/18723	8.71e-06	2.06e-04	78
GO:0031397	Colorectum	AD	negative regulation of protein ubiquitination	34/3918	83/18723	2.66e-05	5.04e-04	34
GO:2001020	Colorectum	AD	regulation of response to DNA damage stimulus	71/3918	219/18723	4.38e-05	7.65e-04	71
GO:1903321	Colorectum	AD	negative regulation of protein modification by small protein conjugation or removal	37/3918	95/18723	4.49e-05	7.83e-04	37
GO:0006282	Colorectum	AD	regulation of DNA repair	42/3918	130/18723	1.57e-03	1.32e-02	42
GO:0045995	Colorectum	AD	regulation of embryonic development	24/3918	64/18723	1.72e-03	1.43e-02	24

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0412014	Cervix	CC	Ubiquitin mediated proteolysis	49/1267	142/8465	4.26e-09	7.68e-08	4.54e-08	49
hsa0412015	Cervix	CC	Ubiquitin mediated proteolysis	49/1267	142/8465	4.26e-09	7.68e-08	4.54e-08	49
hsa04120	Colorectum	AD	Ubiquitin mediated proteolysis	58/2092	142/8465	1.46e-05	1.53e-04	9.76e-05	58
hsa041201	Colorectum	AD	Ubiquitin mediated proteolysis	58/2092	142/8465	1.46e-05	1.53e-04	9.76e-05	58
hsa041202	Colorectum	SER	Ubiquitin mediated proteolysis	39/1580	142/8465	6.18e-03	3.66e-02	2.66e-02	39
hsa041203	Colorectum	SER	Ubiquitin mediated proteolysis	39/1580	142/8465	6.18e-03	3.66e-02	2.66e-02	39
hsa041204	Colorectum	MSS	Ubiquitin mediated proteolysis	55/1875	142/8465	5.02e-06	6.00e-05	3.68e-05	55
hsa041205	Colorectum	MSS	Ubiquitin mediated proteolysis	55/1875	142/8465	5.02e-06	6.00e-05	3.68e-05	55
hsa041206	Colorectum	FAP	Ubiquitin mediated proteolysis	51/1404	142/8465	1.55e-08	5.84e-07	3.55e-07	51
hsa041207	Colorectum	FAP	Ubiquitin mediated proteolysis	51/1404	142/8465	1.55e-08	5.84e-07	3.55e-07	51
hsa041208	Colorectum	CRC	Ubiquitin mediated proteolysis	42/1091	142/8465	9.98e-08	6.67e-06	4.52e-06	42
hsa041209	Colorectum	CRC	Ubiquitin mediated proteolysis	42/1091	142/8465	9.98e-08	6.67e-06	4.52e-06	42
hsa0412026	Esophagus	HGIN	Ubiquitin mediated proteolysis	49/1383	142/8465	7.78e-08	1.33e-06	1.06e-06	49
hsa04120111	Esophagus	HGIN	Ubiquitin mediated proteolysis	49/1383	142/8465	7.78e-08	1.33e-06	1.06e-06	49
hsa0412027	Esophagus	ESCC	Ubiquitin mediated proteolysis	122/4205	142/8465	6.53e-20	7.29e-18	3.74e-18	122
hsa0412036	Esophagus	ESCC	Ubiquitin mediated proteolysis	122/4205	142/8465	6.53e-20	7.29e-18	3.74e-18	122
hsa0412010	Liver	NAFLD	Ubiquitin mediated proteolysis	44/1043	142/8465	2.59e-09	1.70e-07	1.37e-07	44
hsa0412011	Liver	NAFLD	Ubiquitin mediated proteolysis	44/1043	142/8465	2.59e-09	1.70e-07	1.37e-07	44
hsa0412021	Liver	Cirrhotic	Ubiquitin mediated proteolysis	72/2530	142/8465	1.32e-07	1.97e-06	1.21e-06	72
hsa0412031	Liver	Cirrhotic	Ubiquitin mediated proteolysis	72/2530	142/8465	1.32e-07	1.97e-06	1.21e-06	72

Page: 1 2

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

TRIP12

SNV

Missense_Mutation

c.4696G>C

p.Asp1566His

p.D1566H

Q14669

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-A8-A08R-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

TRIP12

SNV

Missense_Mutation

c.4291N>T

p.Pro1431Ser

p.P1431S

Q14669

protein_coding

deleterious(0.03)

probably_damaging(0.939)

TCGA-A8-A09M-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

paclitaxel

TRIP12

SNV

Missense_Mutation

c.808N>A

p.Gln270Lys

p.Q270K

Q14669

protein_coding

deleterious_low_confidence(0.02)

possibly_damaging(0.696)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRIP12

SNV

Missense_Mutation

novel

c.5551N>A

p.Glu1851Lys

p.E1851K

Q14669

protein_coding

deleterious(0)

probably_damaging(0.983)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRIP12

SNV

Missense_Mutation

novel

c.4592N>A

p.Arg1531Gln

p.R1531Q

Q14669

protein_coding

deleterious(0.02)

probably_damaging(0.945)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRIP12

SNV

Missense_Mutation

novel

c.80N>C

p.Asp27Ala

p.D27A

Q14669

protein_coding

deleterious_low_confidence(0.01)

benign(0.091)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRIP12

SNV

Missense_Mutation

c.1855N>A

p.Glu619Lys

p.E619K

Q14669

protein_coding

deleterious(0)

benign(0.001)

TCGA-AN-A0FK-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

TRIP12

SNV

Missense_Mutation

c.3370N>A

p.Ala1124Thr

p.A1124T

Q14669

protein_coding

tolerated(0.15)

benign(0.1)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

TRIP12

SNV

Missense_Mutation

rs373429636

c.2426N>T

p.Ala809Val

p.A809V

Q14669

protein_coding

tolerated(0.51)

possibly_damaging(0.868)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRIP12

insertion

Frame_Shift_Ins

novel

c.5557_5558insGAATGGAAGAAGA

p.Lys1853ArgfsTer32

p.K1853Rfs*32

Q14669

protein_coding

TCGA-AN-A0AL-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1